期刊
JOURNAL OF IMMUNOLOGY
卷 198, 期 4, 页码 1381-1386出版社
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1601358
关键词
-
类别
资金
- Teva
- Teva Pharmaceuticals
- Opexa Therapeutics
- U.S. Department of Veterans Affairs, Biomedical Laboratory Research and Development [I01BX001674]
Advances in translational neuroimmunology over the last two decades have revolutionized the treatment of relapsing forms of multiple sclerosis. A pathological hallmark of multiple sclerosis is the presence of leukocytes in the areas of disease activity in the CNS. Natalizumab inhibits the trafficking of lymphocytes from the blood into the brain and spinal cord by blocking the adhesion molecule alpha(4)-integrin. Representing the enormous success of a molecular targeted approach, natalizumab was the first mAb approved for the treatment of relapsing-remitting multiple sclerosis. However, only a few months after its approval, natalizumab was withdrawn from the market because of an unanticipated life threatening adverse effect: progressive multifocal leukoencephalopathy. Natalizumab was later reintroduced with required adherence to a strict monitoring program. In this article, we review the bench-to-bedside journey of natalizumab, along with the lessons learned from postmarketing studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据